Aripiprazole-d8-1

Aripiprazole (1,1,2,2,3,3,4,4-d8) is the deuterium labeled Aripiprazole. Aripiprazole (OPC-14597) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM[1][2].

Product Specifications

CAS Number

[1089115-04-7]

Product Name Alternative

OPC-14597-d8-1

UNSPSC

12352005

Hazard Statement

H225-H302+H332-H319

Target

5-HT Receptor; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Field of Research

Neurological Disease

Purity

99.86

Solubility

10 mM in DMSO|DMF : ≥ 30mg/mL|DMSO : ≥ 25mg/mL|Ethanol : ≥ 1mg/mL

Smiles

O=C1NC2=C(C=CC(OC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])N3CCN(C4=CC=CC(Cl)=C4Cl)CC3)=C2)CC1

Molecular Formula

C23H19D8Cl2N3O2

Molecular Weight

456.43

Precautions

P210-P233-P240-P241-P242-P243-P261-P264-P270-P271-P280-P303+P361+P353-P304+P340-P305+P351+P338-P330-P370+P378-P403+P235-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Stip E, Tourjman V. et al. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Ther. 2010;32 Suppl 1:S3-20.|[3]Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul;302 (1) :381-9.|[4]Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64 (15) :1715-36.|[5]Nagasaka Y, Oda K, Iwatsubo T, Kawamura A, Usui T. Nagasaka Y, Oda K, Iwatsubo T, Kawamura A, Usui T. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier. Biopharm Drug Dispos. 2012 Jul 27. doi: 10.1002/bdd.1801.